anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-28. Anything still debated is marked as such rather than presented as settled.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
=== Articles === "Ending America's Endless War." Foreign Affairs, June 24, 2019 "Washington's Dangerous New Consensus on China." Foreign Affairs, June 17, 2021 "A Revolution in American Foreign Policy." Foreign Affairs, March 18, 2024 "Democrats must choose: The elites or the working class." The Boston Globe, November 10, 2024 "Bernie Sanders: Kennedy Must Resign." The New York Times, August 30, 2025
== Properties == Ammonium sulfate becomes ferroelectric at temperatures below −49.5 °C (−57.1 °F). At room temperature it crystallises in the orthorhombic system, with cell sizes of a = 7.729 Å, b = 10.560 Å, c = 5.951 Å. When chilled into the ferrorelectric state, the symmetry of the crystal changes to space group Pna21.
While neurotherapy is a relatively young medical treatment in conventional Western biomedicine (that relies on a scientific approach and evidence-based practice), different age-old cultural practices of traditional Indian, Egyptian, and Chinese medicine have been using neuromodulation elements thousands of years ago. Long before humans discovered the science of electricity, ancient physicians used electric currents to treat various physical and mental conditions, including epilepsy, vertigo, and depression. In the ancient world, nature fulfilled many roles now served by technology, including providing sources of electricity. Before electricity was formally understood, people utilized electric fish to deliver therapeutic shocks. The Egyptians knew of the Nile catfish (Malapterurus electricus), capable of producing electric shocks. A depiction of this fish, dating back to 2750 BC, is found in a mural in the tomb of the architect Ti at Saqqara, Egypt. Egyptians weren't the only Mediterranean culture to feature the catfish in their art; similar murals appeared in the Roman city of Pompeii some 3,000 years later, though 1,000 miles to the north. While these murals don't confirm whether the fish were used medically, ancient Egyptian writings on papyri from 4,700 years ago document their use in pain relief. Later historians like Pliny and Plutarch also noted that Egyptians employed electric eels to treat joint pain, migraines, depression, and epilepsy.
Sources: en.wikipedia.org
Traditional nickel catalyst methanizers are designed to only convert CO and CO2 to methane. Due to this limitation, deactivation commonly occurs when other compounds are present in the sample matrix, such as olefins and sulfur containing compounds. Thus, the use of methanizers often requires complex valve systems that may include backflush and heartcutting. Nickel catalyst replacement and conditioning steps are time consuming and require operator skill to perform properly.
== Diseases affected by IGF == Studies of recent interest show that the Insulin/IGF axis play an important role in aging. Nematodes, fruit-flies, and other organisms have an increased life span when the gene equivalent to the mammalian insulin is knocked out. It is somewhat difficult to relate this finding to mammals, however, because there are many genes (at least 37 in the nematode Caenorhabditis elegans) in smaller organisms that are "insulin-like" or "IGF-1-like", whereas in mammals insulin-like proteins comprise only seven members (insulin, IGFs, relaxins, EPIL, and relaxin-like factor). The human insulin-like genes have apparently distinct roles with some but less crosstalk presumably because there are multiple insulin-receptor-like proteins in humans. Simpler organisms typically have fewer receptors; for example, only one insulin-like receptor exists in the nematode C. elegans. Additionally, C. elegans do not have specialized organs such as the (Islets of Langerhans), which sense insulin in response to glucose homeostasis. Moreover, IGF1 affects lifespan in nematodes by causing dauer formation, a developmental stage of C. elegans larva. There is no mammalian correlate. Therefore, it is an open question as to whether either IGF-1 or insulin in the mammal may perturb aging, although there is the suggestion that dietary restriction phenomena may be related. Other studies are beginning to uncover the important role the IGFs play in diseases such as cancer and diabetes, showing for instance that IGF-1 stimulates growth of both prostate and breast cancer cells.
A potential risk of frequent repeated long-term use of LSD and other serotonergic psychedelics is cardiac fibrosis and valvulopathy due to serotonin 5-HT2B receptor agonism. This may also be the case with microdosing. However, the risks are theoretical, and more research is needed to see if these complications can actually occur with psychedelics. A preliminary animal study found that chronic microdosing of LSD did not result in heart structure changes or valvulopathy in rodents. Research appears to be mixed on whether LSD is a potent serotonin 5-HT2B receptor agonist or not, with some studies finding it to be essentially inactive.
Antibody Solutions is a privately held American contract research organization headquartered in Santa Clara, California. It provides research and discovery services and fit-for-purpose antibodies to biopharmaceutical and diagnostic companies and academic researchers worldwide. The company’s services include monoclonal and polyclonal antibody and antigen development, molecular modeling, antibody sequencing and engineering, bioreactor technology, pharmacokinetic studies, antibody epitope binning, peptide synthesis, immunoassay development, ligand-binding assay analysis, and support for CAR-T research.
Sources: en.wikipedia.org
=== Lawsuits === In the late 1980s, Barker accused the American Humane Society and the United Activists for Animal Rights of condoning animal cruelty on the set of Project X and in several other media projects on the basis of allowing a cattle prod and a gun on set, and a rumored beating of a chimpanzee on set. American Humane responded by suing Barker for $10 million, citing libel, slander and invasion of privacy. American Humane claimed that there had been a two-year "vendetta" against them behind the accusations. In a series of public advertisements along with the lawsuit, American Humane responded to Barker's claims that his allegations were made based on insufficient and misleading information. The suit was eventually settled by Barker's insurance company, which paid American Humane $300,000. In 1994, former model Dian Parkinson filed a lawsuit against Barker alleging sexual harassment following a three-year affair while working on The Price Is Right. Parkinson, who alleged that she was extorted by threats of firing, later dropped her lawsuit, claiming the stress from the ordeal was damaging her health. In 1995, model Holly Hallstrom left The Price Is Right and later filed suit against Barker, alleging that the reason she was fired was not so much because of her 14-pound (6.4 kg) medication-mediated weight gain (as documented) but because, to Barker's displeasure, she refused to give false information to the media regarding Parkinson's suit, as she alleges Barker had requested she do.
On November 10, 2025 on Live with Kelly and Mark, Larter talked about the importance of working with Higher Ground of Sun Valley, Idaho; her father was in the U.S. Army and deployed to Vietnam during the Vietnam War.
Donkey Kong Country for the SNES helped Nintendo's comeback against Sega. Doom, released 1993, helped drive adoption of IBM PC compatibles as a major video gaming platform. By late 1995, it was estimated that Doom was installed on more computers than the Microsoft Windows operating system. Myst and The 7th Guest, both released in 1993, drove adoption of CD-ROM drives for personal computers. Virtua Fighter 2, Nights into Dreams, and Sakura Wars are the killer apps for the Sega Saturn. Euro 96 and Sega Rally Championship are major system-sellers for the Sega Saturn in the United Kingdom, with the latter becoming the fastest selling CD game. Dragon Ball Z: Legends served as a killer app for the Sega Saturn in Portugal. Die Hard Arcade and Fighters Megamix boosted the Sega Saturn's sales in the United States. Ridge Racer, Tekken, Wipeout, Tomb Raider, and Crash Bandicoot are the killer apps for the PlayStation. Tomb Raider was released for the Sega Saturn first and for MS-DOS at the same time, but the games contributed substantially to the original PlayStation's early success. Final Fantasy VII is another killer app for the PlayStation. Computing Japan magazine said that it was largely responsible for the PlayStation's global installed base increasing 60% from 10 million units sold by November 1996 to 16 million units sold by May 1997. Super Mario 64 and GoldenEye 007 are the killer apps for the Nintendo 64. Virtua Fighter 3, Sonic Adventure, and The House of the Dead 2 are the killer apps for the Dreamcast. NFL 2K is a killer app for the Dreamcast in the United States.
==== Vacuum system ==== During the drying process, a vacuum of 50–100 microbar is applied, by the vacuum system, to remove the solvent. A two-stage rotary vacuum pump is used, however, if the chamber is large then multiple pumps are needed. This system compresses non-condensable gases through the condenser.
According to Ren Naiqiang, a contemporary who had worked under Liu's government, it was only through the promotion of Buddhism that Liu was able to stabilize his rule after the retreat to Xikang. Upon arriving in Kangding, Liu reportedly invited several famous lamas to gather at his residence to teach him scriptures and dharma. Liu would turn prayer wheels and chant mantras. After these sessions, the lamas spread the word that Liu was in fact the reincarnation of the protector Vajrapani, which greatly enhanced his reputation amongst the people of Kham.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.